Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Among authors: guehring h. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H. Montalban X, et al. Among authors: guehring h. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):1-9. doi: 10.1136/jnnp-2022-328799. Epub 2022 Nov 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36418156 Free PMC article. Clinical Trial.
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Montalban X, et al. Among authors: guehring h. Mult Scler. 2024 Apr;30(4-5):558-570. doi: 10.1177/13524585241234783. Epub 2024 Mar 4. Mult Scler. 2024. PMID: 38436271 Free PMC article. Clinical Trial.
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M. Wallace DJ, et al. Among authors: guehring h. ACR Open Rheumatol. 2023 Jan;5(1):38-48. doi: 10.1002/acr2.11511. Epub 2022 Dec 18. ACR Open Rheumatol. 2023. PMID: 36530019 Free PMC article.
Safety, Tolerability, and Pharmacodynamics of the ADAMTS-5 Nanobody M6495: Two Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies in Healthy Subjects and Patients With Osteoarthritis.
Bihlet AR, Balchen T, Goteti K, Sonne J, Ladel C, Karsdal MA, Ona V, Moreau F, Waterhouse R, Bay-Jensen AC, Guehring H. Bihlet AR, et al. Among authors: guehring h. ACR Open Rheumatol. 2024 Apr;6(4):205-213. doi: 10.1002/acr2.11610. Epub 2024 Feb 4. ACR Open Rheumatol. 2024. PMID: 38311369 Free PMC article.
Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study.
Bay-Jensen AC, Manginelli AA, Karsdal M, Luo Y, He Y, Michaelis M, Guehring H, Ladel C. Bay-Jensen AC, et al. Among authors: guehring h. Osteoarthritis Cartilage. 2022 Jan;30(1):92-99. doi: 10.1016/j.joca.2021.10.008. Epub 2021 Nov 1. Osteoarthritis Cartilage. 2022. PMID: 34737064 Free article. Clinical Trial.
Response letter to the Editor.
Conaghan PG, Guehring H, Moreau F, Daelken B, Ladel C, Guenther O, Reinstrup Bihlet A, Wirth W, Eckstein F, Hochberg M. Conaghan PG, et al. Among authors: guehring h. Semin Arthritis Rheum. 2022 Feb;52:151839. doi: 10.1016/j.semarthrit.2021.05.001. Epub 2021 May 8. Semin Arthritis Rheum. 2022. PMID: 34006385 Free article. No abstract available.
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.
Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, Byrjalsen I, Andersen JR, Daelken B, Guenther O, Ladel C, Michaelis M, Conaghan PG. Eckstein F, et al. Among authors: guehring h. Ann Rheum Dis. 2021 Aug;80(8):1062-1069. doi: 10.1136/annrheumdis-2020-219181. Epub 2021 May 7. Ann Rheum Dis. 2021. PMID: 33962962 Free PMC article. Clinical Trial.
33 results